EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study

Keiko Tanimura iD, Takayuki Takeda iD, Akihiro Yoshimura iD, Ryoichi Honda, Shiho Goda, Shinsuke Shiotsu iD, Mototaka Fukui, Yusuke Chihara, Kiyoaki Uryu, Shota Takei, Yuki Katayama, Makoto Hibino iD und 2 weitere

Cancers · 01.09.2023 · 15 (17) · 4358

DOI: 10.3390/cancers15174358 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 01.09.2023. Verfasst von Keiko Tanimura und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Durvalumab consolidation after chemoradiotherapy (CRT) is a standard treatment for locally advanced non-small cell lung cancer (NSCLC). However, studies on immunological and nutritional markers to predict progression-free survival (PFS) and overall survival (OS) are inadequate. Systemic inflammation causes cancer cachexia and negatively affects immunotherapy efficacy, which also reflects survival outcomes. Patients and Methods: We retrospectively investigated 126 patients from seven institutes in Japan.

Results

The modified Glasgow Prognostic Score (mGPS) values, before and after CRT, were the essential predictors among the evaluated indices. A systemic inflammation-based prognostic risk classification was created by combining mGPS values before CRT, and C-reactive protein (CRP) levels after CRT, to distinguish tumor-derived inflammation from CRT-induced inflammation. Patients were classified into high-risk (n = 31) and low-risk (n = 95) groups, and the high-risk group had a significantly shorter median PFS of 7.2 months and an OS of 19.6 months compared with the low-risk group. The hazard ratios for PFS and OS were 2.47 (95% confidence interval [CI]: 1.46–4.19, p < 0.001) and 3.62 (95% CI: 1.79–7.33, p < 0.001), respectively. This association was also observed in the subgroup with programmed cell death ligand 1 expression of ≥50%, but not in the

Schlagwörter

Stichwörter der Autor:innen

C-reactive proteinchemoradiotherapydurvalumab consolidationinflammationmodified Glasgow prognostic scorenon-small cell lung cancer

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan.
  • Department of Respiratory Medicine, Asahi General Hospital, Asahi 289-2511, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan.
  • Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Japan.
  • Department of Respiratory Medicine, Yao Tokushukai General Hospital, Yao 581-0011, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

ORCID-Profile: Keiko Tanimura, Takayuki Takeda, Akihiro Yoshimura, Shinsuke Shiotsu, Makoto Hibino, Tadaaki Yamada, Koichi Takayama

Zitieren

APA

Tanimura, K., Takeda, T., Yoshimura, A., Honda, R., Goda, S., Shiotsu, S., Fukui, M., Chihara, Y., Uryu, K., Takei, S., Katayama, Y., Hibino, M., Yamada, T., & Takayama, K. (2023). Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers, 15(17), 4358. https://doi.org/10.3390/cancers15174358

Vancouver

Tanimura K, Takeda T, Yoshimura A, Honda R, Goda S, Shiotsu S, et al. Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers. 2023;15(17):4358. doi:10.3390/cancers15174358

BibTeX
@article{Tanimura2023,
  author = {Tanimura, Keiko and Takeda, Takayuki and Yoshimura, Akihiro and Honda, Ryoichi and Goda, Shiho and Shiotsu, Shinsuke and Fukui, Mototaka and Chihara, Yusuke and Uryu, Kiyoaki and Takei, Shota and Katayama, Yuki and Hibino, Makoto and Yamada, Tadaaki and Takayama, Koichi},
  title = {Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {17},
  pages = {4358},
  doi = {10.3390/cancers15174358}
}
Kostenlos starten →